Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

39.77USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$39.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
412,130
52-wk High
$153.98
52-wk Low
$39.47

Latest Key Developments (Source: Significant Developments)

Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel
Wednesday, 11 Apr 2018 08:30am EDT 

April 11 (Reuters) - TESARO Inc ::TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL.FURTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.MEDISON WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE ZEJULA IN ALL INDICATIONS, EXCLUDING PROSTATE CANCER, IN ISRAEL.MEDISON TO ALSO BE RESPONSIBLE FOR ANY POTENTIAL PATIENT ACCESS PROGRAMS PRIOR TO REGULATORY APPROVAL.  Full Article

Tesaro Inc Q4 Loss Per Share $3.35
Tuesday, 27 Feb 2018 04:05pm EST 

Feb 27 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS.Q4 LOSS PER SHARE $3.35.Q4 REVENUE $48 MILLION VERSUS $4.9 MILLION.SEES 2018 TOTAL REVENUE, NET, WORLDWIDE (FY) IN RANGE $310 MLNTO $345 MILLION.TESARO - ANTICIPATES CASH AND CASH EQUIVALENTS BALANCE TO DECLINE BY $150 MILLION DURING Q1.QUARTERLY DECLINES IN CASH AND CASH EQUIVALENTS ARE EXPECTED TO MODERATE OVER COURSE OF 2018, AND IN Q4 OF 2018.PLANS TO DRAW $200 MILLION IN 2018 FROM ITS AVAILABLE TERM LOAN FACILITY.ANTICIPATES YEAR-END 2018 CASH AND CASH EQUIVALENTS TO BE APPROXIMATELY $400 MILLION.  Full Article

Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer
Monday, 26 Feb 2018 03:00pm EST 

Feb 26 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER.TESARO INC - ‍PLANNED TRIAL WILL BE CONDUCTED BY GENENTECH AND IS EXPECTED TO BEGIN MID-2018​.TESARO INC - ‍COLLABORATION INCLUDES TESTING EXPERIMENTAL COMBINATION IN MORPHEUS, ROCHE'S CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM​.  Full Article

Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion
Friday, 12 Jan 2018 05:30pm EST 

Jan 12 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION.TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS.TESARO - ANAPHYLAXIS, ANAPHYLACTIC SHOCK HAVE BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING, SOME REQUIRING HOSPITALIZATION.TESARO - OTHER "SERIOUS" HYPERSENSITIVITY REACTIONS HAVE ALSO BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING.TESARO - MOST REACTIONS HAVE OCCURRED DURING OR SOON AFTER INFUSION OF VARUBI INJECTABLE EMULSION AND WITHIN FIRST FEW MINUTES OF ADMINISTRATION.  Full Article

Tesaro secures $500 million non-dilutive term loan financing
Tuesday, 21 Nov 2017 08:00am EST 

Nov 21 (Reuters) - Tesaro Inc :Tesaro secures $500 million non-dilutive term loan financing.Loans will mature in December 2024​.Loan facility provides Tesaro with up to $500 million of borrowing capacity available in two tranches​.Plan to use proceeds to strengthen PARP inhibitor franchise in ovarian cancer, expand development of Zejula in other tumor types​.  Full Article

Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Tesaro Inc :Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer.Tesaro Inc - ‍approval supported by "robust" data from a randomized phase 3 trial​.Tesaro Inc - ‍Tesaro plans to launch Zejula in Germany and UK this December, with launches in additional European countries to follow beginning in 2018​.  Full Article

Tesaro reports Q3 loss per share $0.47
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Tesaro Inc ::Tesaro announces third-quarter 2017 operating results.Q3 loss per share $0.47.Q3 revenue $142.8 million versus I/B/E/S view $132.8 million.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Tesaro Inc - ‍positive CHMP opinion issued for zejula in e.u. & commercial launch anticipated to begin by year-end​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 10:19am EDT 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

EU Medicines Agency publishes recommendations for Sept 2017
Friday, 15 Sep 2017 07:55am EDT 

Sept 15 (Reuters) - EU MEDICINES AGENCY::EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TESARO INC'S <<>> NIRAPARIB DRUG FOR TREATMENT OF RECURRENT OVARIAN CANCER.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF JANSSEN-CILAG INTERNATIONAL N.V.'S GUSELKUMAB DRUG FOR TREATMENT OF PLAQUE PSORIASIS.  Full Article

Tesaro Inc Q2 loss per share $2.82
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Tesaro Inc :Tesaro announces second-quarter 2017 operating results.Q2 loss per share $2.82.Q2 earnings per share view $-2.49 -- Thomson Reuters I/B/E/S.Qtrly total revenues $35.8 million versus $29.5 million.  Full Article

BRIEF-Tesaro Announces Collaboration To Evaluate Zejula In Combination With Anti-PD-L1 Cancer Immunotherapy, MEK Inhibitor In Platinum-Sensitive Ovarian Cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE ZEJULA® IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY AND MEK INHIBITOR IN PLATINUM-SENSITIVE OVARIAN CANCER